<DOC>
	<DOCNO>NCT00864760</DOCNO>
	<brief_summary>The purpose study compare relative bioavailability 800 mg Gabapentin Tablets Purepac Pharmaceutical Co. 400 mg ( 2 x 400 mg ) NEURONTIN® Parke-Davis fasting condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Gabapentin 800 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , single-dose , two-way crossover design fast condition Official Title : A Relative Bioavailability Study 800 mg Gabapentin Tablets versus 400 mg Gabapentin Capsules Under Fasting Conditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Screening Demographics : All volunteer select study healthy men 18 45 year age , inclusive , time dosing . The weight range exceed ± 15 % height body frame per Desirable Weights Men• 1983 Metropolitan Height Weight Table . Screening Procedures : Each volunteer complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase HIV antibody hepatitis B surface antigen screen URINALYSIS : pH , albumin , sugar , acetone , bilirubin , occult blood microscopic analysis URINE DRUG SCREEN : ethyl alcohol . amphetamine . barbiturate , benzodiazepine , cannabinoids . cocaine metabolite , opiates phencyclidine . Volunteers recent history drug alcohol addiction abuse . Volunteers presence ofa clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined medical investigator ) . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen . Volunteers demonstrate positive drug abuse screen screen study . Volunteers history allergic response ( ) gabapentin relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers clinically significant illness 4 week prior Period I dose ( determine medical investigator . Volunteers currently use tobacco product . Volunteers take drug know induce inhibit hepatic drug metabolism 30 day prior Period I dose . Volunteers report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood four week complete study . Volunteers donate plasma ( e.g . plasmaphoresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Volunteers report receive investigational drug within 30 day prior Period I dose . Volunteers report take systemic prescription medication 14 day prior Period I dose .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Gabapentin</keyword>
	<keyword>Healthy subject</keyword>
</DOC>